The 1 Canadian Stock I'd Buy and Hold Forever in a TFSA for AI Exposure
Written by Amy Legate-Wolfe at The Motley Fool Canada
Artificial intelligence (AI) is rapidly transforming the landscape of numerous industries across the globe, and the healthcare sector is certainly no exception to this profound shift. Many Canadian investors are looking for a way to gain exposure to the exciting potential of AI within the tax-advantaged confines of their Tax-Free Savings Account (TFSA). That's why WELL Health Technologies (TSX:WELL) stands out as a particularly compelling and forward-thinking choice. This AI stock is strategically positioning itself at the forefront of this technological revolution within healthcare.
WELL Health operates as a comprehensive digital healthcare company that is actively integrating the power of AI into its diverse range of services. The AI stock's overarching aim is to leverage these advanced technologies to significantly enhance the quality of patient care while simultaneously streamlining the operational efficiencies of healthcare providers.
WELL Health's AI initiatives are quite innovative and include the development and deployment of tools such as WELL AI Voice. This is designed to assist healthcare professionals with clinical documentation through voice recognition and natural language processing. Furthermore, WELL AI Decision Support aims to provide clinicians with valuable insights and recommendations based on patient data to support more accurate and efficient diagnoses and treatment plans.
From a financial perspective, WELL Health has demonstrated a pattern of robust and impressive growth in recent periods. In the full fiscal year of 2024, the AI stock reported annual revenue of $919.7 million. This marked a substantial 19% increase compared to the revenue figures from the previous year. The AI stock did face certain challenges during this period. These included deferred revenue recognition from its Circle Medical acquisition and some uncertainties regarding collections at its CRH Medical division. Even so, WELL Health still achieved a noteworthy net income of $29.1 million. This represents a significant 74.9% increase in net income compared to the $16.6 million reported in 2023, indicating improved profitability. Furthermore, WELL Health reported a record free cash flow attributable to its shareholders of $49.3 million. This represents a healthy 16.3% increase on a year-over-year basis.
Looking ahead to the current fiscal year of 2025, WELL Health has provided a positive and optimistic outlook for its financial performance. The AI stock projected its revenue to fall within the range of $1.4 billion to $1.5 billion. This forward-looking guidance reflects the anticipated recognition of the deferred revenue from the Circle Medical acquisition as well as the consolidation of the financial results of HEALWELL AI. This revenue projection signals the company's expectation for continued strong growth in the coming year.
Investing in WELL Health through a TFSA offers Canadian investors the significant advantage of tax-free growth on their investments. Any capital gains realized from an appreciation in the company's stock price, as well as any dividends that WELL Health may choose to pay out in the future, will not be subject to Canadian income taxes if held within a TFSA. This tax-free compounding can significantly enhance the long-term returns of an investment, particularly in a growth-oriented company like WELL Health that is operating in a rapidly expanding sector. WELL Health benefits from a strategic focus on the integration of AI into healthcare, strong recent financial performance, and proactive strategic acquisitions. All considered, the AI stock presents a potentially promising opportunity for long-term investors who are seeking exposure to the dynamic intersection of healthcare and cutting-edge technology within the Canadian market.
The post The 1 Canadian Stock I'd Buy and Hold Forever in a TFSA for AI Exposure appeared first on The Motley Fool Canada.
Before you buy stock in WELL Health Technologies, consider this:
The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and WELL Health Technologies wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.
Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $20,697.16!*
Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.
See the Top Stocks * Returns as of 3/20/25
More reading
Best Canadian Stocks to Buy in 2025
Market Volatility Toolkit
4 Secrets of TFSA Millionaires
Beginner Investors: 4 Top Canadian Stocks to Buy for 2025
5 Years From Now, You'll Probably Wish You Grabbed These Stocks
Subscribe to Motley Fool Canada on YouTube
Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Pantheon Resources PLC Announces New Executive Team Appointments
LONDON, UK / / June 9, 2025 / Pantheon Resources plc (AIM:PANR) ("Pantheon" or the "Company"), an oil and gas company developing the Kodiak and Ahpun oil fields in close proximity to pipeline and transportation infrastructure on Alaska's North Slope, is pleased to announce the following appointments to the Executive Team to complete the next phase of its strategic plan-transitioning to development and production and listing on a senior US exchange. Appointment of Tralisa Maraj as Chief Financial OfficerTralisa Maraj has been appointed Chief Financial Officer ("CFO"), succeeding Phil Patman. Tralisa's appointment will be effective 14 July, 2025. In her role as CFO, Tralisa will lead the Finance Team to complete the transformation of Pantheon from a pre-revenue AIM-listed enterprise to a material Alaska North Slope producer listed on a senior U.S. exchange. She brings with her more than 25 years of experience, including having previously been the CFO of two publicly listed companies. Tralisa's career began at Price Waterhouse Coopers in Trinidad. Having established herself as a Finance Executive, she became corporate controller at Remora Oil and Gas, followed by her appointment as CFO for Canadian-listed CGX Energy, and most recently, as CFO of the US-listed LiveWire Group Inc. Tralisa is a chartered accountant (UK) and licensed CPA in Texas. Appointment of Erich Krumanocker as Chief Development OfficerErich Krumanocker has been appointed Chief Development Officer ("CDO"), succeeding Bob Rosenthal, to spearhead the Company's subsurface technical leadership. Bob has indicated his desire to step down from the Board of Directors and retire from the Company at the conclusion of the Company's upcoming board meeting on 13 June, 2025. In his role as CDO, Erich will manage the transition of projects from exploration and appraisal through to development and production. Erich brings with him over 25 years of global experience in driving development, operations and project execution at scale across multiple continents. Erich's career originated as a Petroleum Engineer with BP plc on the North Slope of Alaska, with vast experience in the North Sea, Azerbaijan and the U.S., with his BP career culminating as a VP of Production and Operations. Erich joins Pantheon most recently from Microsoft, where he served as a Partner leading digital transformation across the manufacturing and energy sectors. Max Easley, Chief Executive Officer, commented: "We are delighted to welcome Tralisa and Erich to the Pantheon Executive Team. They will be key in enacting our pivot from a world-class exploration and appraisal team to an equally successful development and operations team. Pantheon will benefit from a combined 50 years of international experience between the two. I also want to thank Phil Patman for his efforts in delivering a strong financial platform for growth through this transition and an ultimate US listing." David Hobbs, Pantheon's Chairman, added: "I would like to add my welcome to Tralisa and Erich. In addition, I also want to express my personal gratitude to Bob Rosenthal, who has been a key member of the leadership of the Company. He was a founder of Pantheon some 20 years ago, then became a founder of Great Bear a few years later. Bob returned to Pantheon 7 years ago to help with the acquisition of Great Bear and then lead the technical team through the journey of discovering and appraising the Ahpun and Kodiak fields to demonstrate the potential for resources that are now independently certified at some 1.6 billion barrels of ANS Crude and 6.6 tcf of natural gas. His leadership has helped position the Company to be a significant part of Alaska's energy future." Further information on these appointments:As part of these appointments, and to align with other executives and the wider interests of shareholders, the new executives will receive the following: One-off grant of 375,000 Restricted Stock Units under the Employee Share Ownership Plan ("ESOP") announced in October 2024, vesting over three years 750,000 options with various time-based and operational vesting criteria Be eligible for ongoing standard senior executive grants under the ESOP The Company expects to grant these awards as soon as administratively and regulatorily practicable. An additional announcement, including further details of their terms, will be made once they are awarded. As is common with US-based businesses, it is not anticipated that the CFO or CDO role will be a Board position. The following details in relation to the appointment of Tralisa Maraj are disclosed in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules: Tralisa Sita Maraj (aged 50) has held the following directorships and/or partnerships in the past five years: Current directorships or partnerships Previous directorships or partnerships Aliana Consulting LLC All About the Blade MJ LLC Cyber App Solutions Corp (trading as Proton Green) LiveWire EV LLC LiveWire France SAS LiveWire Germany GMBH LiveWire Motorcycles Canada Inc LiveWire Netherlands BV LiveWire Switzerland GmbH LiveWire UK Ltd StaCyc LLC Stratovate Ventures & Solutions Group LLC The Rusty Hook Galveston LLC TMJ Realty Group LLC CGX Energy Management Corp. CGX Resources Inc. GCIE Holdings Ltd Grand Canal Industrial Estates Inc. ON Energy Inc. There is no further information to be disclosed in relation to the appointment of Tralisa Maraj pursuant to AIM Rule 17 or Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies. -ENDS- For further information, please contact: UK Corporate and Investor Relations ContactPantheon Resources plcJustin Hondris+44 20 7484 5361contact@ Nominated Adviser and BrokerCanaccord Genuity LimitedHenry Fitzgerald-O'Connor, James Asensio, Charlie Hammond+44 20 7523 8000 Public Relations ContactBlytheRayTim Blythe, Megan Ray, Matthew Bowld+44 20 7138 3204 USA Investor Relations ContactMZ GroupLucas Zimmerman, Ian Scargill+1 949 259 4987PTHRF@ About Pantheon ResourcesPantheon Resources plc is an AIM-listed Oil & Gas company focused on developing its 100% owned Ahpun and Kodiak fields located on State of Alaska land on the North Slope, onshore USA. Independently certified best estimate contingent recoverable resources attributable to these projects currently total c. 1.6 billion barrels of ANS crude and 6.6 Tcf (trillion cubic feet) of associated natural gas. The Company owns 100% working interest in c. 259,000 acres. Pantheon's stated objective is to demonstrate sustainable market recognition of a value of $5-$10/bbl of recoverable resources by end 2028. This is based on bringing the Ahpun field forward to FID and producing into the TAPS main oil line (ANS crude) by the end of 2028. The Gas Sales Precedent Agreement signed with AGDC (Alaska Gasline Development Corporation) provides the potential for Pantheon's natural gas to be produced into the proposed 807-mile pipeline from the North Slope to Southcentral Alaska during 2029. Once the Company achieves financial self-sufficiency, it will apply the resultant cashflows to support the FID on the Kodiak field planned, subject to regulatory approvals, targeted by the end of 2028 or early 2029. A major differentiator to other ANS projects is the close proximity to existing roads and pipelines which offers a significant competitive advantage to Pantheon, allowing for shorter development timeframes, materially lower infrastructure costs and the ability to support the development with a significantly lower pre-cashflow funding requirement than is typical in Alaska. Furthermore, the low CO2 content of the associated gas allows export into the planned natural gas pipeline from the North Slope to Southcentral Alaska without significant pre-treatment. The Company's project portfolio has been endorsed by world-renowned experts. Netherland, Sewell & Associates estimate a 2C contingent recoverable resource in the Kodiak project that total 1,208 mmbbl (million barrels) of ANS crude and 5,396 bcf (billion cubic feet) of natural gas. Cawley Gillespie & Associates estimate 2C contingent recoverable resources for Ahpun's western topset horizons at 282 mmbbl of ANS crude and 803 bcf of natural gas. Lee Keeling & Associates estimated possible reserves and 2C contingent recoverable resources totalling 79 mmbbl of ANS crude and 424 bcf natural gas. For more information visit This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Pantheon Resources PLC View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
2 hours ago
- Bloomberg
Meta in Talks for Scale AI Multi-Billion Investment
Live on Bloomberg TV CC-Transcript 00:00Not exactly a household name. What do scale AI do. And how significant is the investment? Yeah, absolutely. Few people have heard outside of the world of technology and of course of this company, but it has grown in prominence. And now, of course, it's making headlines with this potential investment, 0 billion from META, as you say, one of the biggest private sector investments that we would have seen for years. So Scale AI it focuses on one of the three key components that you need to build out large language models, which is data. So you have energy chips and data, though those are the three main components that come together. And scale AI is squarely focused on data. So they train up, or at least they build out quality data that these models then feed in to train on and they hire PhDs and others to help work through that data and quantify it and tag it. So that's essentially the business model. They've also providing their own solutions into enterprise and have been pushing into defence as well. And I think what this deal tells us is a few things. One Meta of course, that Mark Zuckerberg is not going anywhere in terms of its investments around A.I.. They've pledged to invest at least $60 billion this year and 10 billion now for scale A.I.. If this, of course, comes to pass, so Meta is full bore on the focus on AI, particularly as well around data, it's a reminder that data is becoming a key battleground because along with energy and chips getting hold of the data, quality data is becoming increasingly difficult for these large language models. And so there is a fight on that spectrum as well. And then the third part of this, I think, in terms of what it tells us is defence technology Meta is increasingly working with the Pentagon, particularly further around things like virtual helmets and AI infused helmets for the military. And scale AI already has relationships with the Pentagon. So I think it's also a reminder that matter is getting closer in terms of defence technology as well. So on all three levels, I think those are the significance In terms of the deals that came through this company. Scale AI was valued at 14 billion USD back in 2024. You can imagine that that valuation is much higher now. Yeah. And also we've got London Tech Week kicking off today. What's the top of the agenda? Well, I was talking about data and energy and chips while chips will be front and center because Jensen Huang of nvidia will be giving the keynote speech at London Tech week later this morning alongside the Prime Minister Keir Starmer. Nvidia also expected to announce Jensen Huang some investments here in the UK around training the workforce to be able to use these A.I. applications. They've pledged to train about 100,000 people up until about 2030, investing in the R & D space as well in Bristol, Bristol here in the UK. So the focus is going to be on Jensen Huang has to say at that keynote speech and those investments and how the UK is trying to position itself in this AI race versus the US versus China and also as well versus their counterparts across the channel in Paris because France is also hosting Viva Tech, which is a big tech event and Jensen Huang will be going there as well. And France has been able to build out an AI ecosystem with tax cuts. That is something that arguably the UK government be looking for, which is desperate for growth. And there is one solution for this UK government. They hope to drive growth levels higher in the UK.
Medscape
2 hours ago
- Medscape
AI Scribes Cutting GPs' Admin and Boosting Patient Care
Artificial intelligence (AI) scribing tools are increasingly being used in NHS settings to enhance patient care and free up staff time. In April, the Department of Health and Social Care announced support for NHS doctors to adopt AI tools that 'bulldoze bureaucracy,' allowing clinicians to focus more on their patients and less on documentation. This follows a multi-site evaluation led by Great Ormond Street Hospital for Children, London, England, and funded by NHS England. The trial tested ambient voice technologies (AVTs) that listen to and transcribe consultations in real time. More than 7000 patients took part across settings including accident and emergency, primary care, community services, and mental health. Interim data from the trial showed increased productivity and more time spent on direct care, particularly in emergency settings. Current AI Scribing Tools in Use Several AI scribing tools are already being used within the NHS. Health technology company Accurx recently teamed up with Tandem Health to launch Accurx Scribe, a tool that can transcribe, summarise, and code patient consultations into a trust's clinical records, with functionality to write back to EMIS and SystmOne. It is currently being rolled out across GP practices using Accurx. At the Royal Wolverhampton NHS Trust, a pilot of CLEARNotes is underway. The tool listens to patient consultations and generates a structured summary of the discussion. Meanwhile, Heidi Health is being used by about 40% of GPs and is being piloted in 15 NHS trusts. The AVT tool provides real-time transcription, without storing audio files, in order to address patients' privacy concerns. GP Practices See Significant Benefits At Modality, a group of general practices in West Yorkshire, Heidi has been installed for all GPs and advanced clinical practitioners. Tom Ratcliffe, a GP partner and digital transformation clinical lead for the group, said: 'Clinicians find that it saves time and reduces their administrative burden, particularly around generating clinical correspondence after consultations.' Tom Ratcliffe Ratcliffe described using an AI scribing tool as 'quite transformative' and particularly beneficial for clinicians who are slower typists or who take longer to write detailed notes. 'One of the really significant benefits we've experienced is that by having an ambient scribe writing the notes while you're speaking with a patient, it enables you to focus more on them,' he told Medscape News UK . 'That's really important, as you're then picking up on non-verbal cues that you can easily miss when you're distracted by the computer.' With GPs having between 30 and 50 clinical contacts per day, 'having to think about exactly what to write for each of those encounters is quite a drain on your mental capacity,' Ratcliffe said. 'My colleagues and I have all found using an ambient scribe helps to reduce your cognitive load. Having a consistent format for the notes for every encounter is also helpful,' he added. Patient Consent and Data Security Educating patients about the software is an important consideration. Thomas Kelly, co-founder and chief executive of Heidi Health, said clinicians are advised to obtain consent before using the tool and to explain to patients how an AI scribe works and what they can expect during a consultation. Thomas Kelly 'Patients can also learn more through a range of resources that GPs can put up in their practices that explain how Heidi works,' Kelly said. A transcription of the consultation will be generated, 'but the audio is not permanently recorded or stored in a way that could ever be breached,' he explained. 'It's just being turned into that documentation in real time, and this process is happening on Heidi's servers in the UK.' However, when a session is deleted from Heidi's servers, 'it's deleted for everyone, and there is no way it can be retrieved.' Ratcliffe said that patients have reacted positively to their Modality GP using an AI scribing tool. 'With all the digital innovations we've introduced, we've always had patients who raised very reasonable questions about the privacy of their data,' he said. 'But the level of patient acceptance of using Heidi has been incredibly high.' Each patient is asked to give their consent for the scribing tool to be used. 'I haven't heard of a single example of a patient declining use in an encounter, and we've done probably hundreds or thousands of these now,' said Ratcliffe. Accuracy Concerns Addressed Andrew Noble works within the frailty service at Jean Bishop Integrated Care Centre in East Hull, England. He uses Heidi for consultations lasting up to an hour, which require lengthy administration time. Andrew Noble Staff training on the system emphasises vigilance about possible AI hallucinations in output. According to Noble, one or two minor errors might occur during an hour-long consultation transcription. However, for shorter appointments, lasting 15 minutes, clinicians might expect error-free note-taking from the AI scribe. Use of the tool has significantly improved the quality of note-taking. 'The Heidi AI scribe halved the number of spelling mistakes, and it reduced the number of abbreviations quite significantly as well,' said Noble. Mistakes might include US spellings of antibiotics or the scribe mishearing the name of a medication. 'But we do have human error when inputting our own notes, so those things were already happening from time to time,' Noble observed. Ratcliffe tested multiple AI scribe options before selecting Heidi Health. All platforms occasionally made minor errors. 'Anyone who uses any form of generative AI does find it will occasionally confabulate or hallucinate,' he said. 'One of the key parts of our training was around educating clinicians on the importance of understanding that their role has gone from spending lots of time typing up notes to carefully reading a transcript and checking for any potential issues.' Overall, 'we haven't found that the error rate is high enough that means it's unsafe or not practical to use,' said Ratcliffe. Game-Changing Technology? Health Secretary Wes Streeting has described AI as a catalyst that will revolutionise healthcare. GPs appear to share this optimism. 'This was something that we worked really hard to roll out quickly because we did feel that it was game-changing,' Ratcliffe explained. 'I think it has been game-changing for a lot of our clinicians. When used properly, it can make a big difference.' With GPs working 'above and beyond,' Ratcliffe believes that AI scribing tools 'could help us to move back to a safer place in terms of making our workload more manageable.'
